BioSig and Streamex merge to raise $1.1 billion in funding to focus on gold RWA

BioSig Technologies, a Nasdaq-listed medical device technology company, announced that it has completed a merger with Streamex Exchange Corporation, also listed on Nasdaq, and signed a financing agreement of up to $1.1 billion to accelerate its layout in the field of real-world asset (RWA) tokenization.

According to the announcement, the financing agreement includes the sale of $100 million worth of senior secured convertible bonds and $1 billion in equity credit lines. The transaction was jointly led by Cantor Fitzgerald, a global asset custody and financial services company. It is worth noting that Cantor Fitzgerald is also the asset custodian of stablecoin issuer Tether, and its participation adds credibility to the financing.

This strategic move marks that BioSig Technologies is transforming from a medical technology company to an RWA infrastructure promoter. The company plans to focus on promoting commodities on the chain, with the primary focus on gold tokenization. According to industry estimates, the global commodity market is as large as $142 trillion, and RWA tokenization is seen as a key channel connecting traditional finance and the blockchain world.

Through this merger and financing, BioSig plans to build on Streamex's experience in digital asset trading and technology development to create a commodity chain solution for institutions and promote the application of blockchain in physical asset registration, settlement and trading.

The transaction also shows that as the RWA model matures, more and more traditional listed companies begin to see it as a strategic growth opportunity and transform towards new finance through capital and technology integration.